Heart Defects, Congenital Clinical Trial
Official title:
Genes Causing Congenital Ebstein's Anomaly
This study will investigate Ebstein's anomaly, a congenital abnormality of the tricuspid
valve of the heart and try to identify the genetic origins of the disease.
Adults and children 2 years of age and older with Ebstein's anomaly and healthy volunteers
may be eligible for this study. Participants undergo the following procedures:
- Blood tests: Three tube of blood will be collected, with the total amount limited to
about half a teaspon for each two pounds of body weight.
- Saliva sample collection: A small amount of saliva is collected by spitting into a
sterile container.
- Oral (cheek) swab: Cells are collected from the mouth using a soft brush to swab the
inside lining of the cheek.
- Electrocardiogram: The electrical activity of the heart is recorded using electrodes
placed on the chest.
- Echocardiogram: Heart function is assessed using ultrasound.
The goal of this study is to elucidate the genetic basis for the congenital heart disease (CHD) known as Ebstein's anomaly. These studies complement ongoing research studies using mouse models to recover mutations causing structural heart defects associated with human CHD. By elucidating the underlying genetic causes for Ebstien's anomaly, it may be possible to improve risk assessments as well as facilitate the development of new strategies for prevention and disease management. These studies are important for early diagnosis and the management of complications associated with surviving adults with Ebstein's anomaly, some of whom have undergone surgical correction and others that are unoperated. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05330338 -
Genetics of Ventriculo-arterial Discordance
|
N/A | |
Withdrawn |
NCT03405636 -
Xeltis Pulmonary Valved Conduit Safety and Performance Study
|
N/A | |
Completed |
NCT02443662 -
Colloid Osmotic Pressure in Patients With Fontan Circulation
|
||
Terminated |
NCT02519335 -
Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation
|
Phase 1 | |
Completed |
NCT01835392 -
Neuroprotective Effects of Remote Ischemic Preconditioning (RIPC) During Infant Cardiac Surgery
|
N/A | |
Completed |
NCT00371891 -
Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)
|
Phase 4 | |
Completed |
NCT03035552 -
CTICU Pacifier Activated Music Player and Mother's Voice
|
N/A | |
Recruiting |
NCT04581668 -
Impact of NAVA Ventilation on Brain Oxygenation and Perfusion in Children With Congenital Heart Disease
|
N/A | |
Enrolling by invitation |
NCT04866537 -
Evaluation of the Diagnostic Performance of Specialized Fetal Cardiac Ultrasound in the CPDPN - Arc Alpin Network
|
||
Completed |
NCT03049540 -
Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function
|
Phase 3 | |
Completed |
NCT02377674 -
Safety and Performance of the COR-VG-001 Conduit in Pediatric Patients for Extracardiac Total Cavopulmonary Connection
|
N/A | |
Completed |
NCT01679275 -
Pre-operative Cerebral Oxygenation in Neonates With Congenital Heart Disease
|
||
Terminated |
NCT00543309 -
Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery
|
Phase 2 | |
Completed |
NCT03957512 -
Livet Skal Leves (A Life to Live)
|
||
Recruiting |
NCT06005428 -
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
|
Phase 2 | |
Recruiting |
NCT02691689 -
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions
|
N/A | |
Completed |
NCT02306057 -
Fluid Balance in Children Undergoing Fontan Surgery
|
N/A | |
Recruiting |
NCT02157597 -
NIRS Guidance Trail in Children's Heart Surgery
|
N/A | |
Completed |
NCT01570933 -
Feasibility Study Over the NAVA Mode in Noninvasive Ventilation After Cardiac Surgery in Infants.
|
Phase 4 | |
Completed |
NCT00396877 -
Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation
|
Phase 3 |